Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024

PR Newswire

DUBLIN , April 29, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2024 financial results and provide a business update after market close on Monday, May 13, 2024 . An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET ( 2:00 pm PT / 10:00 pm IST ) that day.

Conference Call Information

To participate in the live call by telephone, please pre-register here . Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's website at www.theravance.com , under the Investors section, Events and Presentations.

A replay of the webcast will be available on Theravance Biopharma's website for 30 days through June 12, 2024 .

About Theravance Biopharma

Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference ^® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI ^® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.

For more information, please visit www.theravance.com .

THERAVANCE BIOPHARMA ^® , THERAVANCE ^® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

YUPELRI ^® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.

Contact:
investor.relations@theravance.com
650-808-4045

View original content to download multimedia: https://www.prnewswire.com/news-releases/theravance-biopharma-to-report-first-quarter-2024-financial-results-on-may-13-2024-302129720.html